Hyperfine, Inc. to participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference. MWN-AI** Summary. Hyperfine, Inc. (Nasdaq: HYPR), an innovative health technology company, will be participating in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10th. The company is renowned for developing the Swoop(R) system, the first FDA-cleared AI-powered portable MRI system designed specifically for brain imaging. This groundbreaking technology aims to revolutionize patient care by making MRI imaging more accessible and feasible in various clinical settings. The Swoop(R) Portable MRI system is a notable advancement, utilizing ultra-low-field magnetic resonance imaging to produce detailed images of the brain's internal structure, offering crucial information for diagnosing patients across all age groups. This portable MRI solution is particularly advantageous for situations where traditional imaging may be impractical, thus expanding the scope of diagnostic capabilities directly at the point of care. Founded by Dr. Jonathan Rothberg within the entrepreneurial incubator 4Catalyzer, Hyperfine emphasizes its mission to enhance global patient care through transformative, accessible diagnostic imaging. The vision behind the Swoop(R) system exemplifies a commitment to improving healthcare outcomes by integrating advanced technology with everyday medical practices. During the upcoming conference, Hyperfine management will hold in-person meetings to engage with investors. Interested parties are encouraged to coordinate with their Lake Street representatives to schedule discussions. The comprehensive goal of Hyperfine is to redefine the methodology of brain imaging and enhance the utility of diagnostic imaging for clinicians. For more information, stakeholders can visit Hyperfine's official website, HyperfineMRI.com, to learn more about its products and mission. MWN-AI** Analysis. Hyperfine, Inc. (Nasdaq: HYPR) will be participating in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10th, an excellent opportunity for investors to gain insights into the company's innovative capabilities, particularly its Swoop(R) portable MRI system. As an emerging leader in diagnostic imaging, Hyperfine has gained FDA clearance for its ultra-low-field MRI technology, which positions the company well in a rapidly evolving healthcare landscape. The Swoop(R) system's portability and accessibility can potentially revolutionize brain imaging by making it feasible in various clinical contexts, from emergency rooms to remote locations. This unique approach addresses gaps in traditional imaging, increasing patient throughput and providing critical diagnostic capability when time is of the essence. Notably, Hyperfine's commitment to affordable and clinically relevant technology aligns with current healthcare trends focused on cost containment and improved patient outcomes. For investors, the participation at the conference signifies confidence in the company's growth trajectory and the expansion of its market presence. As the healthcare industry increasingly emphasizes point-of-care solutions and personalized medicine, Hyperfine's innovative offerings may gain traction, attracting interest from hospitals and clinics looking to enhance their diagnostic capabilities. Nevertheless, potential investors should remain cautious. The healthcare technology sector is highly competitive, with significant barriers to entry. Continuous R&D investment is critical for maintaining a technological advantage, as well as navigating regulatory landscapes. Additionally, as Hyperfine seeks to penetrate broader markets, execution challenges could arise. In conclusion, while Hyperfine presents a compelling investment opportunity ahead of the conference - favorably positioned within a growing niche - it is essential for stakeholders to weigh the inherent risks against the potential for substantial returns. Engaging with management during this event could provide further clarity on strategic initiatives and market positioning. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. August 31, 2026 08:15:00 am Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain - the Swoop(R) system - today announced plans to participate in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10th. Management will be hosting in-person meetings. To schedule a meeting with management, please reach out to your Lake Street representative, or the investor contact below. About the Swoop(R) Portable MRI Systems The Swoop(R) Portable MR Imaging(R) Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop(R) system - the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop(R) system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com. Hyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine. Investor Contact Webb Campbell Gilmartin Group LLC [email protected] FAQ**. How does Hyperfine Inc. HYPR plan to utilize the feedback from the Lake Street Capital Markets conference to enhance the impact of the Swoop(R) system in clinical settings? Hyperfine Inc. plans to leverage feedback from the Lake Street Capital Markets conference to refine the Swoop(R) system's functionality and usability in clinical settings, ultimately enhancing its integration and effectiveness in patient care. What challenges does Hyperfine Inc. HYPR anticipate in expanding the adoption of its FDA-cleared portable MRI systems in various healthcare environments? Hyperfine Inc. anticipates challenges in expanding adoption of its portable MRI systems, including integration with existing workflows, navigating regulatory hurdles in diverse healthcare environments, and addressing the need for training healthcare staff on new technology. Can Hyperfine Inc. HYPR provide any recent data or case studies illustrating the effectiveness of the Swoop(R) system in patient diagnostics and treatment outcomes? As of now, there are no publicly available recent data or case studies from Hyperfine Inc. regarding the Swoop(R) system's effectiveness in patient diagnostics and treatment outcomes post-2026. What are Hyperfine Inc. HYPR's future plans for innovation or improvements in their portable MRI technology following the success of the Swoop(R) system? Hyperfine Inc. plans to enhance their portable MRI technology by focusing on increased accessibility, improved imaging capabilities, and expanding their product offerings to further integrate with healthcare systems, following the success of the Swoop(R) system. **MWN-AI FAQ is based on asking OpenAI questions about Hyperfine Inc. (NASDAQ: HYPR).

Hyperfine reported second-quarter 2026 revenue of $3.9 million, up 45% year-over-year, marking its second-highest quarter ever. The medical imaging company sold 12 systems, a 50% increase from the prior year, with strong international contributions. Gross margin exceeded 50% for the fourth consecutive quarter, reaching 50.7%. The company posted a net loss of $9.3 million, though this included non-cash warrant liability losses. Cash burn improved 9% in the first half compared to the previous year. Hyperfine ended the quarter with $43.5 million in cash, extending its runway into 2028. The company is expanding internationally, achieving CE and UKCA approvals and entering India. It plans to submit for FDA contrast labelling approval by year-end, which could open new reimbursement opportunities. Management expects significant second-half revenue growth driven by hospital budget cycles, office placements, and new software releases.